Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoptin open-label extension in phenylketonuria
2004-004513-41Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2005
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sapropterin in phenylketonuria (PKU) (3 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Blood phenylalanine levels at the end of each dosing period, Safety and tolerability of long-term Phenoptin treatment and 1 more. Started Jun 2005; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2004-004513-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004513-41.